Answers are grounded in this paper and cite their sources.
Case report explores tailored treatment for etoposide hypersensitivity in a child with NGGCT, suggesting effective alternatives.
Hypersensitivity reactions to chemotherapeutic agents have an average incidence of approximately 5%. Hypersensitivity to intravenous etoposide is a rare adverse event. The only escape of Etooside phosphate is not available in low- and middle-income countries. We report here a case of hypersensitivity to etoposide, and early success of a tailored treatment strategy with carboplatin-ifosfamide for this child of NGGCT
No takes yet. Share an insight, caveat, or question.
Bhayana et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: